TFG Advisers LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,028 shares of the company’s stock after purchasing an additional 313 shares during the period. Johnson & Johnson comprises about 1.4% of TFG Advisers LLC’s investment portfolio, making the stock its 17th biggest position. TFG Advisers LLC’s holdings in Johnson & Johnson were worth $2,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. GW&K Investment Management LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at about $35,000. Dark Forest Capital Management LP increased its stake in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after acquiring an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at about $42,000. Kepos Capital LP acquired a new position in Johnson & Johnson in the fourth quarter valued at about $45,000. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $52,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Stock Up 0.8 %
Shares of JNJ stock opened at $168.89 on Wednesday. The firm has a fifty day moving average of $162.21 and a 200-day moving average of $161.03. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a market capitalization of $438.90 billion, a price-to-earnings ratio of 34.19, a P/E/G ratio of 2.93 and a beta of 0.55.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
Analyst Ratings Changes
A number of equities analysts have commented on JNJ shares. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $171.60.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What is an Earnings Surprise?
- JetBlue Airlines May Have Entered A Buy Zone, Check This First
- What is the Shanghai Stock Exchange Composite Index?
- Investors Are Staying Bullish On Marriot International
- CD Calculator: Certificate of Deposit Calculator
- Do Caterpillar’s Results Hint at a Looming Infrastructure Bubble?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
